|Bid||3.1100 x 1000|
|Ask||3.3300 x 1000|
|Day's Range||3.0500 - 3.2700|
|52 Week Range||2.9500 - 13.1000|
|Beta (5Y Monthly)||1.50|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for LIFE
If you want to know who really controls aTyr Pharma, Inc. ( NASDAQ:LIFE ), then you'll have to look at the makeup of...
Atyr Pharma (LIFE) delivered earnings and revenue surprises of -29.41% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
The FDA bestows an Orphan Drug status to aTyr Pharma's (LIFE) lead candidate, efzofitimod, for the treatment of systemic sclerosis. Shares rise.